The European Response to BSE: A Success Story

Food safety authorities across Europe and the meat industry will need to stay vigilant to the threat of bovine spongiform encephalopathy (BSE) even while the number of incidents has dramatically decreased.
calendar icon 17 September 2011
clock icon 9 minute read

A report from Herbert Budka, Vice-Chair of teh European Food Safety Authority’s Panel on Biological Hazards (BIOHAZ) shows that now the number of cases of BSE across the EU has dropped to a trickle with just 44 recorded last year.

However at the beginning of the outbreak, the EFSA report says, some EU politicians refused to implement the European Commission and EFSA recommendations becasue they stubbornly refused to accept that BSE was an EU issue and maintained their countries were free of the disease.

Now that BSE cases are falling to very small numbers and cases of the human disease, variant Creutzfeldt-Jakob Disease (vCJD), are also down to a minimum, the Budka report says that current levels of consumer protection should be maintained and all future changes from well established and highly effective current risk management measures should be based upon sound scientific advice that EFSA will continue to provide.

The report concludes that it will be important to continue and improve the systematic surveillance of animal TSEs, and to refine our diagnostic and laboratory methods and experiments.

BSE was officially first reported in November 1986 in the UK. It became quickly interpreted as likely counterpart in bovines of scrapie, the paramount transmissible spongiform encephalopathy (TSE, prion disease) in sheep and goats.

A landmark epidemiological study by John Wilesmith and co-workers (Wilesmith et al., 1988) identified in 1988 cattle feedstuffs containing ruminant-derived protein (meat-bone meal, MBM) as source for the evolving epidemic that numbered almost 185,000 diagnosed cases in total in the UK and a further 5,500 elsewhere in the EU, with some 2 million infected bovines estimated to have entered the human food chain in the UK.

The first UK response was a ban on feeding MBM to ruminants, as a measure that significantly curbed but did not eliminate the epidemic.

A likely link between BSE and the human disease variant Creutzfeldt-Jakob disease (vCJD) was published in early April 1996 (Will et al., 1996), followed by a media outbreak of apocalyptic scenarios sketching a man-made disaster of then unpredictable proportions. Health authorities were frantically acting to limit damage from BSE not only to human health, but also to agriculture, economies, political credibility and public confidence.

In the UK, the Phillips Inquiry (Lord Phillips et al., 2000) took two and a half years to accrue insight into why and how the BSE saga developed.

"The key conclusions depicted BSE as a consequence of intense farming practices, with significant shortcomings in the way things were done, with sensible measures taken that were not always timely and adequately implemented and enforced, and implicitly guided by the belief that BSE was not a real threat to human health," says the Budka report.

"Moreover, there was too much secrecy and unjustified reassurance by governmental bodies in order to protect the agricultural industry."

Almost simultaneously with publication of the Phillips Report, the second public BSE crisis started in 2000 when first results of active BSE surveillance on the European continent confirmed scientists’ opinion that political claims of “freedom from BSE” in several countries were wishful thinking rather than reality.

As a result, the EU TSE Regulation of 20011 laid down a comprehensive set of harmonised rules for the prevention, control and eradication of TSEs, including an EU-wide total ban on the feeding of animal proteins to farmed animals.

"More or less independent national food safety authorities were now established in most EU countries and the need to separate risk assessment from risk management could no longer be ignored," says Budka.

Since the first BSE crisis of 1996, the European Commission (EC) has embarked on a science-guided response, establishing a TSE/BSE ad hoc Group of their Scientific Steering Committee (SSC) that provided up to 2003 a plethora of opinions on all aspects of BSE and other TSEs (SSC, 1997-2003).

The SSC was a risk assessment and risk advisory body, separated from risk management, which remained with the EC Directorate General for Health & Consumers (DG SANCO).

From December 1997, the SSC adopted their first important documents on the scientific basis to protect human health from BSE, such as the definition of tissues containing most of infectious TSE agents (prions), termed Specific Risk Materials (SRM).

"Regrettably, politicians in several EU Member States (MS) were then unwilling to translate this into legislation, still sticking to their 'freedom from BSE' illusion," the report says.

"It was only after a delay of almost three years that the EU-wide SRM ban, the most important measure to protect public health from BSE, became implemented."

Since 2003, EFSA has taken over the role of science-based advice to the EC on BSE/TSE-related matters, with the BIOHAZ Panel producing an equally impressive amount of opinions and reports (EFSA, 2003-2011) as the former SSC. As a whole, these scientific risk assessments – first by the SCC, then by EFSA – and their translation into adequate measures by national and EC risk managers were the basis of the European response to BSE, which has been a spectacular success story.

This is evident from quantitative data on both the animal and human disease.

First, the prevalence of BSE as detected by current surveillance has come down steadily in the EU to a trickle, from several thousands of cases in the early 2000s, to 44 in 2010 in the EU (11 in the UK) (OIE, 2011).

Second, surveillance of vCJD in the UK indicates that the epidemic, having reached a peak in the year 2000 when there were 28 deaths, has declined to a current incidence of about one diagnosis/death per year (Andrews, 2011).

"Clearly, it is now time to be re-assured but still too early for complacency (Budka et al., 2008)," the report says.

"Given the quantitative indicators of what seems, in the EU, to be the near-extinction of the animal epidemic and control of cattle-to-human transmission, is there anything left for concern?

"Unfortunately, there is."

With BSE, the global disease burden is far from clear in countries with less well-developed surveillance. In humans, the potential continuing person to person spread by blood and blood products remains a problem as seen with the four cases of transfusion-associated vCJD infection to date (Andrews, 2011).

With BSE and other TSEs in animals, the recognition of the wide diversity of prion strains in the field, including three new forms of animal TSEs (L-type Atypical BSE, H-type Atypical BSE and Atypical scrapie), has complicated disease diagnosis and surveillance, as well as scientific assessment of their potential risks to humans.

EFSA and the European Centre for Disease Prevention and Control (ECDC) recently delivered a scientific opinion on any possible epidemiological or molecular association between TSEs in animals and humans (EFSA Panel on Biological Hazards (BIOHAZ) and ECDC, 2011).

This opinion confirmed Classical BSE prions as the only TSE agents demonstrated to be zoonotic so far but the possibility that a small proportion of human cases so far classified as “sporadic” CJD are of zoonotic origin could not be excluded.

Transmission experiments to non-human primates also suggest that some TSE agents in addition to Classical BSE prions in cattle (namely L-type Atypical BSE, Classical BSE in sheep, transmissible mink encephalopathy (TME) and chronic wasting disease (CWD) agents) might have zoonotic potential. In particular the L-type Atypical BSE agent might be similarly or even more virulent to humans than the Classical BSE agent.

While mankind has been in contact with the major TSE of small ruminants for centuries, there is no epidemiological evidence to suggest that classical scrapie is zoonotic; however, experimental transmission data on humanised mice and non-human primates have been very scarce so far.

What does this mean for the future?

The report says thaqt the decline of the BSE epidemic seen by 2005 led to consideration of some relaxation of costly BSE control measures as depicted in the EU TSE Roadmap (EC, 2005), and will inevitably be followed by further relaxation as already outlined in another EU TSE Roadmap 2 of 2010 (EC, 2010). It remains critical that current levels of consumer protection are maintained and all future changes from well established and highly effective current risk management measures are based upon sound scientific advice that EFSA will continue to provide.

Which old issues will remain, and which new issues will become relevant?

For Atypical BSE, the most widely accepted hypothesis is that of a spontaneously arising (“sporadic”) disease in relatively old bovines. If this holds true, it will be impossible to eradicate such a disease which originates de novo; probably we then have to live forever with a ban on SRMs, in particular the central nervous system (CNS), of older cattle.

Given our insufficient knowledge about the true prevalence of atypical animal prion strains in the field, it will be important to continue and improve the systematic surveillance of animal TSEs, and to refine our diagnostic and laboratory methods and experiments.

As some scientific data suggest that there is probably no absolute molecular barrier to transmission of TSE agents between mammalian species (EFSA Panel on Biological Hazards (BIOHAZ) and ECDC, 2011), the issue of a zoonotic potential of prions is likely to remain with us a time.

For human TSEs including sporadic CJD, it will be important to continue systematic surveillance that should be able, as clearly shown with vCJD in the past, eventually to identify emerging new phenotypes or new prion strains.

In sum, at a time when many scientists and most decision makers are no longer interested in prions and their risk, it will be prudent to stay vigilant, although this must be in a way that is balanced with other risks to human and animal health. In the risk assessment area, this will continue to be a challenge for EFSA in the years to come.


Andrews NJ, 2011. Incidence of variant Creutzfeldt-Jakob disease diagnoses and deaths in the UK. January 1994 - December 2010. Health Protection Agency, Centre for Infections, Statistics Unit. Available from:
Budka H, Goossens B and Ru G, 2008. BSE and TSEs: Past, present and future. Trends in Food Science & Technology, 19, S34-S39.
EC (European Commission), 2005. The TSE Roadmap. COM 322 final, Brussels. 24 pp. Available from:
EC (European Commission), 2010. The TSE Roadmap 2. COM 384 final, Brussels. 36 pp. Available from:
EFSA (European Food Safety Authority). BSE and other Transmissible Spongiform Encephalopathies (TSEs) 2003-2011. Available from:
EFSA Panel on Biological Hazards (BIOHAZ) and ECDC (European Centre for Disease Prevention and Control), 2011. Joint Scientific Opinion on any possible epidemiological or molecular association between TSEs in animals and humans. EFSA Journal,9(1):1945, 111 pp., doi:10.2903/j.efsa.2011.1945.
Lord Phillips, Bridgeman J and Ferguson-Smith M, 2000. The BSE Inquiry Report. Available from:
OIE (Organisation Internationale des Epizooties), 2011. Bovine Spongiform Encephalopathy (BSE). Available from:
SSC (Scientific Steering Committee), 1997-2003. Outcome of Discussions. European Commission, Available from:
Wilesmith JW, Wells GAH, Cranwell MP and Ryan JBM, 1988. Bovine spongiform encephalopathy: epidemiological studies. Veterinary Record, 123, 638-644.
Will RG, Ironside JW, Zeidler M, Estibeiro K, Cousens SN, Smith PG, Alperovitch A, Poser S, Pocchiari M and Hofman A, 1996. A new variant of Creutzfeldt-Jakob disease in the UK. The Lancet, 347, 921-925.

September 2011
© 2000 - 2024 - Global Ag Media. All Rights Reserved | No part of this site may be reproduced without permission.